Shares of biotechnology company Vaxgen Inc. on Wednesday soared 88 percent in after hours trading when the company announced it was negotiating to sell rights to its experimental anthrax vaccine in Britain.
California Biotech firm negotiates with Britain to supply anthrax vaccine.